Phase 2CompletedAge-related condition
The Moran AMD Genetic Testing Assessment Study (MAGENTA)
A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration
- Sponsor
- Paul S. Bernstein (Academic or other)
- Enrollment
- 80 enrolled
- Conditions
- Age-Related Macular Degeneration; Genetic Testing; Nutritional Biomarkers
- Interventions
- Early disclosure of genetic testing results; Late disclosure of genetic testing results
- Ages
- adults
- Registry
- NCT05265624
Full record on ClinicalTrials.gov
From the registry
The goals of this study are: To assess the impact of genetic testing for Age-related Macular Degeneration (AMD) on lifestyle behaviors as measured by systemic and ocular carotenoid status.
Primary outcomes
- Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Reflectance Spectroscopy
- Change in Skin Carotenoid Status in Response to Genetic Risk Disclosure as Measured by Resonance Raman Spectroscopy
History
Results first posted
Last registry update
Primary completion
Started
Registered
Papers citing this trial
- Carotenoid Status and Psychological Impact of Presymptomatic Macular Degeneration Genetic Risk Assessment: The MAGENTA Randomized Trial
Ophthalmology science
- The value of pre-symptomatic genetic risk assessment for age-related macular degeneration: the Moran AMD Genetic Testing Assessment (MAGENTA) study-a study protocol for a randomized controlled trial
Trials